Non-alcoholic fatty liver disease (NAFLD) is a prevalent and serious health concern, often overlooked due to its silent presentation. This article aims to provide an in-depth understanding of NAFLD, its implications, and management strategies.
NAFLD affects approximately 25% of the global population. Risk factors include obesity, type 2 diabetes, and metabolic syndrome. Despite its association with these conditions, NAFLD can occur in individuals without any apparent risk factors, making it a complex disease to diagnose and manage.
The pathogenesis of NAFLD remains multifactorial, involving insulin resistance, oxidative stress, and inflammation. The disease spectrum ranges from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, and eventually cirrhosis. Understanding the underlying mechanisms is crucial for the development of effective therapeutic strategies.
NAFLD often presents asymptomatically, making early detection challenging. Diagnosis is typically incidental, following abnormal liver function tests or imaging studies. Liver biopsy remains the gold standard for diagnosis, although non-invasive methods, such as elastography, are gaining popularity.
Current management of NAFLD focuses on lifestyle modifications, including weight loss and exercise. Pharmacological interventions are limited to patients with NASH and fibrosis. Future research should focus on identifying novel therapeutic targets and improving early detection strategies.
NAFLD is a significant health concern with a complex pathophysiology and silent presentation. A comprehensive understanding of its epidemiology, risk factors, pathophysiology, and management is essential for healthcare professionals. Future research should focus on improving early detection and developing effective therapeutic strategies.
1.
New Nanoparticles Can Destroy Undruggable Cancer Proteins
2.
Brain MRI Surveillance Alone Helps Preserve Cognition in Small Cell Lung Cancer
3.
NEET SS Counseling 2023: MCC provides information on DNB SS Medical Oncology seats available at ESIC Medical College and Hospital Faridabad.
4.
Belzutifan Plus Pembro Approved for Adjuvant RCC
5.
Using MRD Status to Deescalate Multiple Myeloma Therapy
1.
Diagnosis and Treatment of Follicular Thyroid Cancer: A Comprehensive Guide
2.
Obesity as a major risk factor for cancer
3.
Unraveling the Genetic Mystery of Hereditary Spherocytosis
4.
Advanced Pathways in Oncology for Better Care
5.
Essential Updates in Hematology in Daily Practice
1.
International Conference on Oncology, Cancer Prevention and Public Health
2.
International Conference on Cancer Nursing and Rehabilitation Strategies
3.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
4.
International Conference on Innovations in Critical Care for Oncology and Cardiology
5.
International Symposium on Oncology, Cardiology and Critical Care Innovations
1.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
3.
Understanding Anemia and Its Common Causes
4.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
5.
Early Cancer Detection Saves Lives
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation